Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New antiplatelet drugs

J E Joseph1, S J Machin

  • 1University College London Medical School, Department of Haematology, UK.

Blood Reviews
|March 3, 1998
PubMed
Summary

Antiplatelet drugs like aspirin, ticlopidine, and clopidogrel are vital for ischemic conditions. Newer agents show promise, but side effects and delivery methods are key considerations for their use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A performance evaluation of a novel human recombinant tissue factor prothrombin time reagent (Revohem<sup>™</sup> PT).

International journal of laboratory hematology·2017
Same author

ICSH recommendations for modified and alternate methods measuring the erythrocyte sedimentation rate.

International journal of laboratory hematology·2017
Same author

Cytomegalovirus-associated thrombocytopenia treated with thrombopoietin receptor agonist.

Internal medicine journal·2016
Same author

Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism.

Journal of thrombosis and haemostasis : JTH·2016
Same author

Recombinant Alpha 2A Interferon-An Effective Maintenance Agent in Essential Thrombocythaemia.

Leukemia & lymphoma·2016
Same author

Resolution of paraneoplastic immune thrombocytopenia following everolimus treatment for metastatic renal cell carcinoma.

Internal medicine journal·2015

Area of Science:

  • Pharmacology and Therapeutics
  • Cardiovascular Medicine

Background:

  • Antiplatelet drugs are essential in managing various vascular disorders, used alone or with other treatments.
  • Aspirin is a long-established, effective antiplatelet agent for ischemic conditions.

Purpose of the Study:

  • To review the efficacy and limitations of current and emerging antiplatelet therapies.
  • To compare aspirin with newer antiplatelet agents like ticlopidine and clopidogrel.
  • To discuss the role of glycoprotein IIb/IIIa antagonists in acute coronary syndromes.

Main Methods:

  • Review of clinical evidence for aspirin, ADP-mediated inhibitors (ticlopidine, clopidogrel), and Gp IIb/IIIa antagonists.
  • Analysis of therapeutic effectiveness and side-effect profiles.
  • Consideration of parenteral versus oral drug development.

Main Results:

  • Aspirin is clinically effective for ischemic conditions.
  • Ticlopidine and clopidogrel, inhibiting ADP-mediated platelet aggregation, are effective, potentially superior to aspirin in some cases, but ticlopidine has significant side effects.
  • Gp IIb/IIIa antagonists significantly improve outcomes in acute coronary syndromes, with ongoing development of oral formulations.

Conclusions:

  • Antiplatelet drug therapy is crucial, with evolving options beyond aspirin.
  • Balancing efficacy with side-effect profiles is critical for agent selection.
  • Further research into oral Gp IIb/IIIa antagonists is warranted.

Related Experiment Videos